MedTrace Logo

Liposomal and Standard Bupivacaine in Thoracic Paravertebral Block for Post-Thoracoscopic Pain

NCT06165991 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 496

Last updated 2026-01-09

No results posted yet for this study

Summary

I. Research purpose

1.1 Main Objective: To investigate the efficacy and safety of bupivacaine liposome thoracic paravertebral nerve block for postoperative analgesia after thoracoscopic lobectomy

1.2 Exploratory Objective: To investigate the noninferiority of bupivacaine liposomes in thoracic paravertebral nerve block with standard bupivacaine

Conditions

  • Thoracic Paravertebral Block
  • Postoperative Analgesia
  • Thoracoscopic Lobectomy

Interventions

DRUG

GroupB:Liposomal bupivacaine and bupivacaine hydrochloride;

Group B::Patients in the intervention group received a mixture of 10 mL of 1.33% liposomal bupivacaine (133 mg) and 10 mL of 0.5% bupivacaine hydrochloride.

DRUG

Group A: bupivacaine hydrochloride;

Group A:Patients in the control group received 20 mL of 0.5% bupivacaine hydrochloride (total dose, 100 mg).

Sponsors & Collaborators

  • Yongtao Sun

    lead OTHER

Principal Investigators

  • Sun Y tao, PH.D · Shandong First Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2026-01-30
Completion
2026-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06165991 on ClinicalTrials.gov